vs
Alkermes plc.（ALKS）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
Alkermes plc.的季度营收约是ROGERS CORP的1.9倍（$384.5M vs $200.5M），Alkermes plc.净利率更高（12.8% vs 2.2%，领先10.6%），ROGERS CORP同比增速更快（5.2% vs -10.6%），Alkermes plc.自由现金流更多（$170.0M vs $1.1M），过去两年Alkermes plc.的营收复合增速更高（4.8% vs -3.3%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
ALKS vs ROG — 直观对比
营收规模更大
ALKS
是对方的1.9倍
$200.5M
营收增速更快
ROG
高出15.8%
-10.6%
净利率更高
ALKS
高出10.6%
2.2%
自由现金流更多
ALKS
多$168.9M
$1.1M
两年增速更快
ALKS
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $200.5M |
| 净利润 | $49.3M | $4.5M |
| 毛利率 | 88.0% | 32.2% |
| 营业利润率 | 15.1% | — |
| 净利率 | 12.8% | 2.2% |
| 营收同比 | -10.6% | 5.2% |
| 净利润同比 | -66.3% | 421.4% |
| 每股收益（稀释后） | $0.29 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKSROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $384.5M | $201.5M | ||
| Q3 25 | $394.2M | $216.0M | ||
| Q2 25 | $390.7M | $202.8M | ||
| Q1 25 | $306.5M | $190.5M | ||
| Q4 24 | $430.0M | $192.2M | ||
| Q3 24 | $378.1M | $210.3M | ||
| Q2 24 | $399.1M | $214.2M |
净利润ALKSROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $49.3M | $4.6M | ||
| Q3 25 | $82.8M | $8.6M | ||
| Q2 25 | $87.1M | $-73.6M | ||
| Q1 25 | $22.5M | $-1.4M | ||
| Q4 24 | $146.5M | $-500.0K | ||
| Q3 24 | $92.4M | $10.7M | ||
| Q2 24 | $91.4M | $8.1M |
毛利率ALKSROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 88.0% | 31.5% | ||
| Q3 25 | 86.9% | 33.5% | ||
| Q2 25 | 87.3% | 31.6% | ||
| Q1 25 | 83.9% | 29.9% | ||
| Q4 24 | 85.6% | 32.1% | ||
| Q3 24 | 83.3% | 35.2% | ||
| Q2 24 | 84.6% | 34.1% |
营业利润率ALKSROG
| Q1 26 | — | — | ||
| Q4 25 | 15.1% | 3.5% | ||
| Q3 25 | 22.6% | 7.3% | ||
| Q2 25 | 23.8% | -33.3% | ||
| Q1 25 | 4.5% | -0.2% | ||
| Q4 24 | 37.8% | -6.6% | ||
| Q3 24 | 27.7% | 6.9% | ||
| Q2 24 | 27.5% | 5.3% |
净利率ALKSROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 12.8% | 2.3% | ||
| Q3 25 | 21.0% | 4.0% | ||
| Q2 25 | 22.3% | -36.3% | ||
| Q1 25 | 7.3% | -0.7% | ||
| Q4 24 | 34.1% | -0.3% | ||
| Q3 24 | 24.4% | 5.1% | ||
| Q2 24 | 22.9% | 3.8% |
每股收益（稀释后）ALKSROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.29 | $0.20 | ||
| Q3 25 | $0.49 | $0.48 | ||
| Q2 25 | $0.52 | $-4.00 | ||
| Q1 25 | $0.13 | $-0.08 | ||
| Q4 24 | $0.88 | $-0.04 | ||
| Q3 24 | $0.55 | $0.58 | ||
| Q2 24 | $0.53 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $1.2B |
| 总资产 | $2.5B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALKSROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $388.6M | $197.0M | ||
| Q3 25 | $616.4M | $167.8M | ||
| Q2 25 | $521.2M | $157.2M | ||
| Q1 25 | $399.8M | $175.6M | ||
| Q4 24 | $291.1M | $159.8M | ||
| Q3 24 | $396.3M | $146.4M | ||
| Q2 24 | $535.1M | $119.9M |
股东权益ALKSROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.8B | $1.2B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.5B | $1.3B | ||
| Q4 24 | $1.5B | $1.3B | ||
| Q3 24 | $1.3B | $1.3B | ||
| Q2 24 | $1.3B | $1.3B |
总资产ALKSROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.5B | $1.4B | ||
| Q3 25 | $2.3B | $1.4B | ||
| Q2 25 | $2.3B | $1.5B | ||
| Q1 25 | $2.1B | $1.5B | ||
| Q4 24 | $2.1B | $1.5B | ||
| Q3 24 | $2.2B | $1.5B | ||
| Q2 24 | $2.2B | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $170.0M | $1.1M |
| 自由现金流率自由现金流/营收 | 44.2% | 0.5% |
| 资本支出强度资本支出/营收 | 0.0% | 2.3% |
| 现金转化率经营现金流/净利润 | 3.45× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $480.3M | $70.1M |
8季度趋势，按日历期对齐
经营现金流ALKSROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $170.1M | $46.9M | ||
| Q3 25 | $101.7M | $28.9M | ||
| Q2 25 | $150.2M | $13.7M | ||
| Q1 25 | $98.8M | $11.7M | ||
| Q4 24 | $190.4M | $33.7M | ||
| Q3 24 | $81.6M | $42.4M | ||
| Q2 24 | $146.0M | $22.9M |
自由现金流ALKSROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $170.0M | $42.2M | ||
| Q3 25 | $84.4M | $21.2M | ||
| Q2 25 | $137.2M | $5.6M | ||
| Q1 25 | $88.7M | $2.1M | ||
| Q4 24 | $180.6M | $18.3M | ||
| Q3 24 | $73.3M | $25.2M | ||
| Q2 24 | $138.9M | $8.8M |
自由现金流率ALKSROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 44.2% | 20.9% | ||
| Q3 25 | 21.4% | 9.8% | ||
| Q2 25 | 35.1% | 2.8% | ||
| Q1 25 | 28.9% | 1.1% | ||
| Q4 24 | 42.0% | 9.5% | ||
| Q3 24 | 19.4% | 12.0% | ||
| Q2 24 | 34.8% | 4.1% |
资本支出强度ALKSROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.0% | 2.3% | ||
| Q3 25 | 4.4% | 3.6% | ||
| Q2 25 | 3.3% | 4.0% | ||
| Q1 25 | 3.3% | 5.0% | ||
| Q4 24 | 2.3% | 8.0% | ||
| Q3 24 | 2.2% | 8.2% | ||
| Q2 24 | 1.8% | 6.6% |
现金转化率ALKSROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 3.45× | 10.20× | ||
| Q3 25 | 1.23× | 3.36× | ||
| Q2 25 | 1.72× | — | ||
| Q1 25 | 4.40× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.88× | 3.96× | ||
| Q2 24 | 1.60× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
ROG
暂无分部数据
